Kornimate/medical-research-clean huggingface dataset:
mindfulness-based dance/movement therapy for chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the purpose of this study is to evaluate the feasibility, acceptability and credibility of a mindfulness-based dance/movement therapy (m-dmt) protocol that is delivered online; to assess and improve methodological procedures for conducting a randomized controlled trial (rct) test of m-dmt; and to demonstrate proof of principle by gathering information about the process of change between m-dmt and a control condition. this is the first study to address the potential of m-dmt as a creative, non-opioid intervention for chronic back pain. therefore, the findings of this study will provide important methodological and protocol data and substantive pilot data necessary for the next phase of this line of research, namely a fully powered rct to evaluate efficacy and treatment mechanisms of action. data obtained as part of this study will be instrumental for informing the systematic evaluation of m-dmt for chronic back pain care.


Eligibility criteria:
inclusion criteria * age \> 18 years * current non-specific clbp that has persisted at least 3 months, and has resulted in pain on at least half the day in the past 6 months * proficient in english * average pain severity and interference ratings \>3/10 on a 0-10 numeric rating scale * if taking pain medication(s), dosage must be stabilized for a minimum of 3 months * patients agree not to seek additional therapies for the duration of this study beyond those already included in their current treatment regimen or new treatments prescribed by their physician * naïve to dmt. * those who have adequate computer literacy (e.g., know how to use a computer to perform basic tasks such as open/send emails, use internet, fill-out online surveys) and access to the virtual delivery format (i.e., internet service and a personal computer device such as laptop, desktop, tablet pc). exclusion criteria: * pregnancy * severe and/or progressive medical, neurological, substance dependence within the last 6 months or severe mental illness (i.e., psychosis, mania) that would prevent active participation * cognitive impairment that prohibits informed consent * back surgery in the last 6 months * low back pain attributable to a recognizable, known specific pathology (e.g. infection, tumor, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome * wheelchair-bound or unable to move without assistance * involvement in impending litigation or judgment for disability or worker's compensation.

Keywords: dance/movement therapy mindfulness-based dance/movement therapy chronic pain management creative arts therapies non-pharmacological intervention online intervention
perceptions of aesthetic outcomes of zigzag and linear scars

Conditions: Linear Scar; Zigzag Scar

Summary: surgical wounds can be closed in several manners. some physicians believe that closure in a straight line produces a scar that is more visible and slightly raised when compared to closure in a zigzagging fashion. the researchers of this study believe that there is no difference in the cosmetic appearance of one type of wound closure over the other. to evaluate this, they will provide a survey with visual aids to volunteers to rate the appearance of a straight line scar versus a zigzag scar.


Eligibility criteria:
inclusion criteria: * male or female * 18 years or older exclusion criteria: * less than 18 years of age

Keywords: cicatrix demonstrate that there is no perception of superiority
radotinib versus imatinib in newly diagnosed philadelphia chromosome and chronic myeloid leukemia chronic phase patients

Conditions: Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Bone Marrow Diseases; Hematologic Diseases

Summary: in this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with philadelphia chromosome-positive (ph+) chronic myelogenous leukemia in the chronic phase (cml-cp).


Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of chronic phase cml within last 3 months * patients with cytogenetically confirmed ph positive cml in early chronic phase exclusion criteria: * patients with philadelphia chromosome negative but bcr-abl positive cml * patients who used imatinib for 8 days or longer before study entry * patients who had been treated with other targeted anti-cancer therapy, except for hydrea or agrylin, which inhibits the growth of leukemic cells * patients with impaired cardiac function * cytologically confirmed cns involvement * severe or uncontrolled chronic medical condition * other significant congenital or acquired bleeding disorders that are not related to underlying leukemia * patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery

Keywords: radotinib cml-cp chronic myeloid leukemia, chronic phase
high-flow conditioned oxygen therapy versus non-invasive ventilation: prevention of post-extubation failure

Conditions: Post-extubation Respiratory Failure

Summary: the main aim is to demonstrate whether the high flow conditioned oxygen therapy reduces the reintubation rate. post-extubation respiratory failure risk will be stratified (as the randomization). in high risk patients high flow conditioned oxygen therapy will be compared with with not conditioned non-invasive mechanical ventilation. in low risk patients comparison will be conventional oxygen therapy. hypercapnic patients will be excluded.


Eligibility criteria:
inclusion criteria: * low risk patients: * any extubated patients after tolerating a spontaneous breathing trial. * high risk patients: * any extubated patients after \>48 hours under mechanical ventilation and any of the following: * \>65 years * cardiac failure as the primary indication of mechanical ventilation * copd * apache ii \>12 points the extubation day * bmi \>30 * inability to manage respiratory secretions * 1 failed spontaneous breathing trial * 1 comorbidity * 7 days under mechanical ventilation exclusion criteria: * \<18 years * thacheotomized patients * recent facial or cervical trauma/surgery * active gastro-intestinal bleeding * lack of cooperation and patients with any failed spontaneous breathing trial because of hypercapnia development.
targeting the neurobiology of rrb in autism using n-acetylcysteine: trial

Conditions: Autism Spectrum Disorder

Summary: the goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using n-acetylcysteine (nac), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. the findings from this research will shed light on the mechanisms of action underlying the clinical benefits of nac and the effects of nac on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. this is a 12-week double-blind, randomized, placebo-controlled trial of nac.


Eligibility criteria:
inclusion criteria: * children between 3 years and 12 years 11 months * diagnosis of autism spectrum disorder confirmed with the autism diagnostic interview- revised and the autism diagnostic observation schedule-2, brief observation of symptoms of autism, or childhood autism rating scale * at least moderate severity of restricted and repetitive behaviors defined by a children's yale-brown obsessive compulsive scale for autism spectrum disorder score ≥ 11 * physical development indicative of prepubescence as defined by criteria for tanner stage 1 * if home address is within 300 miles of the primary study site, participants must pass mr safety screening (e.g., no metal in the body) and attempt baseline neuroimaging (mri or eeg), otherwise baseline neuroimaging is not required for participation * have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days) prior to randomization with no anticipated changes during the trial exclusion criteria: * presence of known genetic abnormalities associated with asd (e.g. fragile x) * current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia) * presence of significant medical problems * the inability of at least one caregiver to speak and read english to a sufficient level * participants taking glutathione agents/prodrugs * history of any adverse effects to glutathione agents/prodrugs * the inability to drink a sample study compound dissolved in liquid

Keywords: magnetic resonance imaging n-acetyl cysteine restricted and repetitive behaviors electroencephalography
assessment of lung inflammation with fdg pet/ct in covid-19

Conditions: COVID-19; FDG PET/CT; Inflammation

Summary: the aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for covid-19. patients admitted with covid-19 from march 27th to may 3rd, 2020 were prospectively enrolled. all patients had an initial chest ct-scan for diagnosis on admission and a second chest ct-scan for follow-up concomitant with a fdg pet/ct between day 6 and day 14 after the onset of symptoms.

\[18f\]-2-fluoro-2-deoxy-d-glucose pet/ct (fdg pet/ct) is a sensitive and quantitative technic for detecting inflammatory process. glucose uptake is correlated with increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes and granulocytes. the aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for covid-19. patients were included if covid-19 was confirmed according to the who guidance (11) by a positive result of rt-pcr assay of nasal and pharyngeal swabs, if they were hospitalized during the time period from day 6 to day 14 of the onset of symptoms, and if their initial (on admission) chest ct-scan presented ground-glass opacities (ggo) or consolidation. group of 13 consecutive patients prospectively enrolled. all patients had an initial chest ct-scan for diagnosis on admission and a second chest ct-scan for follow-up concomitant with a fdg pet/ct between day 6 and day 14 after the onset of symptoms. based on the changes between the two chest ct, patients were classified as follows: * ct worsening: increase of ct abnormalities extent \> 20% or additional ggo or consolidation. conversion of ggo into consolidation was not considered as additional finding. * ct stability: changes of ct abnormalities extent ≤ 20% without additional ggo or consolidation. * ct improvement: decrease of ct abnormalities extent \> 20% without additional ggo or consolidation. based on fdg pet/ct imaging, patients' profiles were classified as follows: * inflammatory: lungs hypermetabolic volume ≥ 50 ml and / or suvmax ≥ 7 * low inflammatory: lungs hypermetabolic volume \< 50 ml and / or suvmax\< 7 patients' short-term clinical outcome was classified as follows: worsening, stability, improvement.

Eligibility criteria:
inclusion criteria: * patients were included if covid-19 was confirmed according to the who guidance (11) by a positive result of rt-pcr assay of nasal and pharyngeal swabs, if they were hospitalized during the time period from day 6 to day 14 of the onset of symptoms, and if their initial (on admission) chest ct-scan presented ground-glass opacities (ggo) or consolidation. exclusion criteria: * patients could not be included if their medical condition was unstable or precluded a safe transfer to the nuclear medicine department, if they were under mechanical ventilation (either non-invasive or invasive), if they were initially referred to the critical care unit, and in case of a pregnancy.
smartcare driven pressure support-non invasive ventilation feasibility study

Conditions: Acute Respiratory Failure

Summary: knowledge-based systems were initially developped to automatically adapt pressure support settings during invasive ventilation, and proved to be at least as efficient as experienced clinicians. non-invasive ventilation has become the standard of care for patients suffering from acute hypercapnic respiratory failure (arf)and has reduced the need for endotracheal intubation in these patients, thus reducing their hospital mortality. niv success or failure is closely related to the tolerance of niv treatment, which is tightly correlated to patient-ventilator synchrony. as severe asynchronies frequently occurs during niv (namely in more than 40% of patients) and as the occurence of asynchronies is related to the use of high pressure support levels, to the presence of leaks and/or to non optimal expiratory trigger settings, very frequent ventilator settings adaptations should allow reducing patient-ventilator asynchronies but require the presence of an experienced clinician at the bedside during niv treatment. a computer-driven ventilator settings adaptation has the adavantage of permitting very frequent ventilator settings adaptation whithout requiring the presence of an experienced clinician at the bedside and could possibly improve patient-ventilator interaction. the aim of the present study is to test the faisability of using the smartcare niv computer-driven system to automatically adapt ventilator settings during non invasive ventilation delivered because of acute respiratory failure.


Eligibility criteria:
inclusion criteria: * acute respiratory failure requiring non invasive ventilation * icu patient equipped with an arterial line. exclusion criteria: * contra-indications to niv: * impaired consciousness * absence of patient cooperation * severe hemodynamic instability * vomiting * facial lesions * indication for immediate intubation * acute neurological problem * poor short term prognosis

Keywords: non invasive ventilation computer-driven system acute respiratory failure
personalized swiss sepsis study

Conditions: Sepsis

Summary: this multi-center study is to focus on patients with sepsis in intensive care units (icus) in order to better understand the complex host-pathogen interaction and clinical heterogeneity associated with sepsis. understanding this heterogeneity may allow the development of novel diagnostic approaches. data from patients will be analyzed using state-of-the art analytical algorithms for biomarker discovery including machine learning and multidimensional mathematical modelling to explore the large datasets generated. in order to discover digital biomarkers for the study endpoints a case-control study design will be used to compare data patterns from patients with sepsis (cases) and those without sepsis (controls).


Eligibility criteria:
inclusion criteria: * patients admitted to an icu on a swiss university hospital. * patients expected to stay at least 24h on the icu inclusion criteria (cases) * present at admission to icu or subsequent development of sepsis 3.0 criteria inclusion criteria (controls) * patients not fulfilling sepsis definition during the icu stay exclusion criteria: * decline of general consent or any other negative statement against using data for research. * patients with a clear elective stay on the icus.

Keywords: clinical data warehouse (cdwh) machine learning data-driven algorithms multi-dimensional modelling
bone denisty change in children with beta thalassemia major

Conditions: Evaluate Bone Denisty Changes in Children With Beta Thalassemia Major

Summary: bone denisty changes in children with beta thalassemia major

beta thalassemia major (tm) is a hereditary disease caused by defective beta globin chain synthesis, resulting in abnormal as well as a decreased quantity of globin chains, ineffective erythropoiesis, haemolysis and increased red blood cell turnover (cooley, etal, 1927). described the first patient with anemia, splenomegaly, cranial \& facial bone enlargement. pathophysiology of bone denisity changes in beta thalassemia major several studies had been previously evaluated; shown that multiple factors may act in concert to produce bone disease in beta thalassemia major (tm) including bone marrow expansion (shamshirsaz, etal, 2003). hypogonadism (anapliotou,saka\&jensen,1998), defective growth hormone-insulin-like growth factor-1 (gh-igf-1) axis (soliman,etal,1998), altered pattern of cytokines (morabito,etal,2007), iron deposit in bone ((bordat,etal,1993),deferoxamine bone toxicity (chan ,etal, 2002),and vitamin d deficiency (dandona, etal, 1987). some of these pathogenic factors, directly and/or indirectly, affect osteoblastic population, leading to depressed bone formation, while others often increase osteoclastic bone resorption. complications of transfusion dependent poorly controlled beta thalassemia major are;(1)-osteoprosis; iron overload impairs osteoid maturation and inhibits local mineralization to form focal osteomalacia. in addition, integration of iron in calcium hydroxyapatite affects the growth of crystals, which causes mineralization failure (chan, etal, 2002), defective growth hormone-insulin-like growth factor-1 (gh-igf-1) axis (soliman, etal, 1998),altered pattern of cytokines (morabito,etal, 2007), iron deposit in bone (bordat, etal, 1993), deferoxamine bone toxicity (chan, etal,2002). and vitamin d deficiency (dandona, etal, 1987). (2)-fractures; the introduction of red blood cell transfusion and concomitant iron chelation therapy has led to improved bone health through various mechanisms. it leads to a reduction in medullary expansion and cortical bone thinning, the reduced incidence of hypogonadism, and a reduction in other endocrine complications such as hypoparathyroidism and metabolic disorders that predispose to low bone density and fractures( multicentre study, italian working group 1995). z-score of bone density will be calculated. z score is the preferred parameter in children. which is calculated as the number of standard deviations above or below the mean for the patient's age, sex,

Eligibility criteria:
inclusion criteria: - patient diagnosed as b thalassemia major of both sexes, age range from 10-18 year, who are poorly controlled on frequant blood transfusion. the patient who doesn't have hb level from 9-10 g/dl, in almost always less than 9 g/dl. exclusion criteria: * known metabolic bone disease. less than 10 year or more than 18 year. bone disease other than hemolytic anemia.
evaluating online messages about colon cancer screening

Conditions: Colonic Cancer

Summary: the goal of the study is to determine, using a choice-based approach, what messages (pulled from various online sites) people find more and less persuasive and shareable on the topic of colorectal cancer screening. as a secondary goal, the study is interested how various information behaviors, such as people's self-reported seeking of health information and encountering of health information, demographic variables, individual difference variables, and message exposure associate with their intentions to adhere to recommended colorectal cancer screening guidelines from the national cancer institute. the study is interested at differences specifically among black and white americans of recommended screening age (45-74).


Eligibility criteria:
inclusion criteria: * identify as white/caucasian or black/african american. exclusion criteria: * do not identify as white/caucasian or black/african american. * previously diagnosed with colorectal cancer
effectiveness and safety of topical ranibizumab for treatment of corneal neovascularization (nv)

Conditions: Corneal Neovascularization

Summary: the purpose of this study is to determine the effectiveness and safety of ranibizumab (lucentis) in treatment of corneal neovascularization.

this is an open label, single site, uncontrolled, single group assignment, safety/efficacy, phase i study of topical administered ranibizumab in subjects with corneal neovascularization. ten eyes of patients with corneal neovascularization will be recruited. patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus will be considered.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age \> 18 years old * patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus exclusion criteria: * has received investigational therapy within 60 days prior to study entry * has received treatment with anti-vegf agents (intraocular or systemic) within 45 days of study entry * concurrent use of systemic anti-vegf agents * full thickness or lamellar keratoplasty within 90 days prior to study entry * ocular surface reconstruction within 90 days prior to study entry * other ocular surgeries within 90 days prior to study entry * corneal or ocular surface infection within 90 days prior to study entry * ocular or periocular malignancy * contact lens (excluding bandage contact lens) within 30 days prior to study entry * persistent epithelial defect (\>1mm2 and ≥14 days duration) within 30 days prior to study entry * systemic, intravitreal, or periocular steroids within 30 days prior to study entry * change in dose/frequency of topical steroids and/or nsaids within 30 days prior to study entry * hypertension: systolic bp \> 150 or diastolic bp \> 90 * history of thromboembolic event within 6 months prior to study entry * current diagnosis of diabetes, pregnancy (positive pregnancy test) or lactation * premenopausal women not using adequate contraception (the following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an iud, or contraceptive hormone implant or patch) * participation in another simultaneous medical investigation or trial.